Daewoong Pharmaceutical’s Enavogliflozin Cuts Leptin Levels Twice as Much as Another Diabetes Drug, Study Finds
AI 요약 정보
- Study: Enblo lowers leptin about twice as much as dapagliflozin
- Daewoong pooled two Phase 3 trials with 427 patients
- Enblo improved HOMA-IR more; weight and HbA1c showed no significant differences
